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Carboxyl (C)-terminal fragments of parathyroid hormone
(PTH) oppose the calcemic, phosphaturic, and bone-resorbing
effects of active hormone. To study the action of these
fragments on 1,25(OH)2D (1,25-dihydroxyvitamin D) synthesis,
we infused parathyroidectomized rats with human or rat
active 1–34 or 1–84 PTH at doses selected to produce similar
calcemic responses. Human active PTH influenced neither
phosphate nor 1,25(OH)2D concentrations. However, active
1–34 rat PTH decreased phosphate to the same level as
vehicle-treated rats and increased 1,25(OH)2D to very high
levels, whereas active 1–84 PTH decreased phosphate but
maintained 1,25(OH)2D. As the latter effect could have been
due to C-terminal fragment generation during its metabolic
breakdown, we infused a mixture of rat C-terminal fragments
alone or with rat 1–34. The C-terminal fragments decreased
1,25(OH)2D and prevented hypocalcemic-induced 1,25(OH)2D
synthesis. When infused with active rat 1–34, they lowered
the 1,25(OH)2D level to that seen with intact rat 1–84. The
C-terminal fragments did not influence either basal or rat
1–34- or 1–84-induced CYP27B1 mRNA levels, suggesting
that their inhibitory effects on 1,25(OH)2D synthesis appears
to be post-transcriptional.
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Carboxyl-terminal (C) fragments constitute 75–80% of
circulating parathyroid hormone (PTH) immunoreactivity
in a normal individual and more than 95% in renal failure
patients.1 Once believed to be biologically inactive, these
fragments have now been demonstrated to exert biological
actions both in vivo and in vitro (see Murray et al.2 for
review). In vivo, in parathyroidectomized (PTX) rats, human
(h) PTH(7–84) and a mixture of hC-PTH fragments (10%
hPTH(7–84) and 45% each of hPTH(39–84) and (53–84))
were able to decrease calcium concentration beyond the effect
of parathyroidectomy,3,4 to reduce phosphate concentration,4
and to antagonize the calcemic or phosphaturic action of
PTH(1–84) or hPTH(1–34).3,4 hPTH(7–84) also diminished
the high bone turnover induced by hPTH(1–84) alone in rats
with renal failure.5 In vitro, the most impressive effect was an
inhibition of calcium resorption elicited not only by
PTH(1–84) and PTH(1–34) but also by 1,25(OH)2 vitamin
D (1,25-dihydroxyvitamin D), prostaglandin E2, and inter-
leukin-11.6 It also promoted osteoblast apoptosis.7 All these
outcomes of C-PTH fragments are opposite and probably
independent of those of PTH(1–84) or (1–34) on the PTH/
PTHrP type 1 receptor. Binding studies7–9 suggest that these
effects may be mediated via a different so-called C-PTH
receptor, but the latter has not yet been cloned successfully.
Surprisingly, nothing has been established about the
possible action of C-PTH fragments on 1,25(OH)2D
synthesis. It is well-known that 1,25(OH)2D impacts the
secretion of PTH(1–84) and the C-PTH/I-PTH ratio in
blood.10–12 Here, we report a negative influence of C-PTH
fragments on 1,25(OH)2D synthesis but not on CYP27B1
mRNA expression in the kidneys. We also explain why it has
been difficult to demonstrate an effect of hPTH(1–84) or
(1–34) preparations on 1,25(OH)2D synthesis.
RESULTS
Table 1 and Figure 1a and b illustrate the biochemical
characteristics of our PTX rat model and the influence of
hPTH and rat(r)PTH(1–34) and (1–84) infusion in these
animals. The dose of each preparation to be infused
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intravenously for 48 h was established in preliminary
experiments, which aimed at the correction of low Ca2þ
concentrations present in PTX rats to the levels observed in
the controls. This was achieved at 0.24 nmol/kg/h for
hPTH(1–84), 0.12 nmol/kg/h for hPTH(1–34), 0.09 nmol/
kg/h for rPTH(1–84), and 0.06 nmol/kg/h for rPTH(1–34).
These doses caused a similar increase of 0.27–0.31 mmol/l in
Ca2þor of 0.54–0.69 mmol/l in total Ca at 48 h (Table 1 and
Figure 1b). The PTX-h- and rPTH(1–84)-infused groups had
a mean body weight slightly lower than that of the sham-
solvent group (Po0.05). The PTX-solvent group was
hypocalcemic (Po0.001) and hyperphosphatemic (Po0.01)
with low to undetectable levels of rPTH (Po0.001)
compared to sham-solvent rats, but its mean 25-hydroxyvi-
tamin D (25(OH)D) and 1,25(OH)2D levels did not differ
from those of the latter group (nonsignificant (NS)).
When infused with hPTH or rPTH preparations at the
preselected doses, all PTX groups significantly increased their
ionized and total calcium concentrations compared to PTX-
solvent group (Po0.001) and to the mean level observed in
sham-solvent rats (NS). The two PTX-hPTH-infused groups
failed to decrease their phosphate concentration to the values
found in sham-solvent rats (Po0.05) and, in fact, remained
similar to PTX-solvent rats (NS). In contrast, both PTX-
rPTH-infused groups decreased their phosphate values to the
concentration in sham-solvent rats (NS) and significantly
lower than in the PTX-solvent group (Po0.05) or the two
PTX-hPTH-infused groups (Po0.05). Mean alkaline phos-
phatase levels did not differ among the various groups. Mean
serum 25(OH)D concentrations were higher in the sham-
solvent group (Po0.01) than in the PTX-h- and rPTH(1–34)
as well as the PTX-hPTH(1–84)-infused groups, but the values
observed did not differ from those of the PTX-solvent group
(NS). The two PTX-hPTH-infused groups decreased their
1,25(OH)2D to lower values than in the sham-solvent group
(Po0.05), the PTX-solvent group (Po0.01) or the PTX-
rPTH(1–34)-infused (Po0.001) and the PTX-rPTH(1–84)-
infused (Po0.05) groups. In contrast, the PTX-rPTH(1–34)
group increased its 1,25(OH)2D concentration to well above
all other groups (Po0.01). The PTX-rPTH(1–84)-infused
group maintained a mean 1,25(OH)2D concentration similar
to the sham- and PTX-solvent groups (NS). Rats infused with
hPTH or rPTH(1–34) preparations had undetectable levels of
hPTH or rPTH in the circulation, as expected. Rats infused
with hPTH(1–84) displayed levels of hPTH(1–4) and (12–23)
that were respectively 10 and 4 times higher than rPTH values
in sham-solvent rats, whereas rPTH(1–84)-infused rats
showed rPTH(1–4) and (13–34) values similar to those of
the latter group.
Table 2 and Figure 1c illustrate the influence of infusion of
a rat C-PTH fragment mixture alone or with rPTH(1–34) on
calcium, phosphate, 25(OH)D, and 1,25(OH)2D concentra-
tions in PTX rats. Infused alone the mixture did not affect the
low total or ionized calcium values and the high phosphate
and 25(OH)D concentrations observed in the PTX-solvent
group. The only exception was the 1,25(OH)2D level, which
became significantly lower than in the PTX-solvent
(Po0.001), the PTX-rPTH(1–34) (Po0.001), the PTX-
rPTH(1–34)þ rmixture (30% rPTH (7.84) and 70% rPTH
(39.84)) (Po0.05), and the rPTH(1–84) (Po0.001) groups,
but was similar to the values in the normocalcemic,
hyperphosphatemic hPTH-infused groups (NS). When
rPTH(1–34) was infused with the rmixture of C-PTH
fragments, the total and ionized calcium values reached were
identical to those obtained during the infusion of
rPTH(1–34) (NS) or rPTH(1–84) (NS) alone, but phosphate
was significantly higher than with rPTH(1–84) (Po0.01),
even if similar to the results with rPTH(1–34) (NS).
1,25(OH)2D concentration declined significantly lower than
with the infusion of rPTH(1–34) alone (Po0.001) and was
identical to the value observed with the rPTH(1–84) infusion
(NS). As expected, rPTH(1–4) was only detectable in the
group infused with rPTH(1–84) (Po0.001), and the level was
similar to that in sham-solvent rats (NS). rPTH(13–34) was
detectable in the rmixture groups and the rPTH(1–84) group.
Its level was higher in the PTX-rmixture group than in the
Table 1 | Bioequivalence: rPTH and hPTH in PTX rats
Groups Parameters Sham-solvent PTX-solvent
PTX-rPTH(1–34)
(0.06 nmol/kg/h)
PTX-rPTH(1–84)
(0.09 nmol/kg/h)
PTX-hPTH(1–34)
(0.12 nmol/kg/h)
PTX-hPTH(1–84)
(0.24 nmol/kg/h)
N 8 9 12 8 8 8
Weight (g) 297716 281728 278726 256720a 289732 252720b
Ca2+ (mmol/l) 1.3170.03 1.0470.03c 1.3370.09f 1.3170.07f 1.3570.06f 1.3370.07f
Ca total (mmol/l) 2.4770.07 1.9570.07c 2.5570.20f 2.4970.19f 2.6470.14f 2.6470.11f
Phosphorus (mmol/l) 2.4770.24 3.0570.37b 2.6670.38d 2.4470.30e 2.9370.37a,i 3.0370.12b,g,j
Alk. phos. (U/l) 329757 2567101 301788 2827106 262761 258774
25(OH)D (nmol/l) 92728 75722 63710b 7676 62716b 64714b
1,25(OH)2D (pmol/l) 116718 133742 234796
c,f 122733h 79729b,e,h,i 75717a,e,h,i
rPTH(1–4) (pmol/l) 3.671.4 070c 070c 3.773.5f,h 070c,k 2.672.9a,f,h
rPTH(13–34) (pmol/l) 12.574.2 0.570.4c 070c,f 7.677.3f,h 070c,f,k 0.270.2c,h,k
hPTH(1–4) (pmol/l) 070 070 070 070 070 44731c,f,h,k
hPTH(12–23) (pmol/l) 070 070 070 070 070 57740c,f,h,k
ANOVA, analysis of variance; hPTH, human parathyroid hormone; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; PTX, parathyroidectomized.
Results are means7s.d. obtained at time 48 h. Statistical analysis by one-way ANOVA on log-transformed values, followed by the Student–Newman–Keuls test.
Sham-solvent vs all PTX groups: aPo0.05; bPo0.01; cPo0.001. PTX-solvent vs PTH-infused PTH groups: dPo0.05; ePo0.01; fPo0.001. PTX-rPTH(1–34) vs other
PTX-PTH-infused groups: gPo0.05; hPo0.001. PTX-rPTH(1–84) vs PTX-hPTH-infused groups: iPo0.05; jPo0.01; kPo0.001.
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PTX-solvent group (Po0.001) and in the PTX-
rPTH(1–34)þ rmixture and rPTH(1–84) groups (Po0.05)
compared to the rPTH(1–34) group, as expected.
Next, the CYP27B1/GAPDH ratio was measured to try to
understand how rC-PTH fragments were exerting their
inhibitory effects on 1,25(OH)2D synthesis (Figure 2). By a
one way analysis of variance, the ratio was very different
among the various groups (Po0.005), but the between-
groups analysis was only significant between the rPTH(1–84)
group and the sham-solvent (Po0.05) or PTX-solvent
(Po0.05) groups even if 50% of the rats in the rPTH(1–34)
and rPTH(1–34)þ rmixture groups also increased their ratio.
The ratio did not differ between the sham-solvent, the PTX-
solvent, and the rmixture alone groups.
DISCUSSION
Our aim was to study the possible influence of C-PTH
fragments on 1,25(OH)2D synthesis induced by a variety of
hPTH or rPTH preparations and to compare the potency of
hPTH and rPTH preparations in this regard. We developed a
PTX rat model infused intravenously over 48 h with various
PTH preparations. These rats had the biochemical character-
istics of hypoparathyroid animals with low calcium, high
phosphate, and very low to undetectable rPTH levels, but
they maintained normal 25(OH)D and 1,25(OH)2D levels.
The absence of a decrease in mean 1,25(OH)2D level in these
rats is best explained by their hypocalcemia, which is a potent
stimulator of 1,25(OH)2D synthesis independently of PTH or
phosphate levels.13–16
We next tested rPTH and hPTH(1–84) and (1–34) in our
PTX rat model at doses that gave a similar calcemic response
for each preparation. Despite the latter common character-
istic, hPTH(1–84) and (1–34) had no effect on the elevated
phosphate level and, in fact, caused a reduction of 25(OH)D
and 1,25(OH)2D levels. The decrease in 25(OH)D concen-
tration is probably best explained by a PTH-induced increase
in 25(OH)D turnover, as demonstrated previously in rats.17
The diminished 1,25(OH)2D concentration reflects both the
lack of influence of hPTH(1–34) and (1–84) preparations on
1,25(OH)2D synthesis, at the selected doses, and the
inhibitory impact of higher calcium concentrations, achieved
with the hPTH preparations, on the same process.13–16 The
doses of hPTH preparations selected for this study are the
lowest required to normalize calcium concentration in PTX
rats and are 16.5 (hPTH(1–84)) and 33 (hPTH(1–34)) times
lower than doses tested by us in earlier experiments.4 It
demonstrates that hPTH preparations are less potent than
their rat counterparts, as expected, but that they also have
different dose dependencies of calcemic vs phosphatemic and
1,25(OH)2D synthetic effects. These discrepancies were not
observed with the two rPTH preparations, which disclosed
similar hypercalcemic, hypophosphatemic, and 1,25(OH)2D
synthetic actions at the chosen concentrations. However,
rPTH(1–34) proved to be a more potent preparation for
stimulation of 1,25(OH)2D synthesis than rPTH(1–84) by
twofold. C-PTH fragments were generated during the
peripheral metabolism of rPTH(1–84), and their levels did
not differ significantly from those seen in sham-solvent
control rats. We thus postulate that the difference in
1,25(OH)2D synthesis noted between these two groups could
be related to the presence of C-PTH fragments issued by
hepatic metabolism in the rPTH(1–84)-infused group.
To study this hypothesis, we infused one group of PTX
rats with a rmixture of C-PTH fragments alone and a second
group with the rmixture and rPTH(1–34). The dose of rC-
PTH fragments selected was three times the dose of
rPTH(1–34), a minimal difference required at least between
the two human preparations to ascertain a biological effect of
C-PTH fragments on calcium concentration.4 The composi-
tion of 30% PTH(7–84) and 70% PTH(39–84) was arbitrary,
but attempted to better duplicate the composition of
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Figure 1 | Calcemic response to various human and rat PTH
preparations in PTX rats. (a) Sham-solvent rats (&) are compared to
PTX-solvent rats, (b) Sham-solvent rats (&) are compared to rats
infused with hPTH(1–34), 0.12 nmol/kg/h (K); hPTH(1–84), 0.24 nmol/
kg/h (m); rPTH(1–34), 0.06 nmol/kg/h (E); and rPTH(1–84), 0.09 nmol/
kg/h (’). (c) PTX-solvent rats (J) are compared to rats infused with
rPTH(1–34) and a mixture of rC-PTH fragments at 0.18 nmol/kg/h
(.) or the mixture alone (m). *Po0.01; ***Po0.001. Ionized calcium
values (Ca2þ ) are presented at all time points and total calcium
values (Cat) only at 48 h.
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circulating PTH, with results from the human model.1 The
mixture alone did not influence calcium, phosphate, or
25(OH)D concentrations in PTX rats but caused a significant
decrease in 1,25(OH)2D below that in PTX-solvent rats or
the rPTH(1–34)- and rPTH(1–84)-infused groups. In fact, it
prevented the hypocalcemia-induced 1,25(OH)2D synthesis
observed in the PTX-solvent group, indicating that rC-PTH
fragments are able to inhibit not only PTH-induced
biological actions but also other hormone- or ion-induced
biological effects, as demonstrated previously in vitro for the
bone-resorbing outcome of 1,25(OH)2D, prostaglandin E2,
and interleukin-11.6 When infused with rPTH(1–34), the
rPTH mixture did not reduce the calcemic effect of
rPTH(1–34), nor did it influence the hypophosphatemic
action of this rPTH preparation, but it decreased
1,25(OH)2D synthesis induced by rPTH(1–34) alone to the
level seen in rPTH(1–84)-infused rats or in sham-solvent
controls, confirming our initial hypothesis.
To establish how the inhibitory effect of rC-PTH fragments
was exerted, we measured CYP27B1 mRNA. The rC-PTH
fragments mixture group, which had the lowest mean
1,25(OH)2D level, presented a CYP27B1/GAPDH ratio similar
to that of the sham- and PTX-solvent groups, indicating an
inhibitory mechanism independent of CYP27B1 mRNA level.
This was also confirmed in the rPTH(1–34), rPTH(1–84), and
rPTH(1–34)þ rmixture groups, which manifested a similar
increase in the CYP27B1/GAPDH ratio in 50% of the rats in
each group while having very different mean 1,25(OH)2D
levels. It remains unclear why only 50% of these 9-week rats
increased their ratio. The CYP27B1 mRNA response of PTX
rats to PTH is more marked in younger rats,18 and ours were
young. The dose of rPTH(1–34) used was minimal in our
study and may have been contributive. Together, these data
suggest that the inhibitory effect of rC-PTH fragments on
calcium- or rPTH-induced 1,25(OH)2D synthesis is mainly
post-transcriptional. As rC-PTH fragments exert an inhibitory
effect both on PTH- and calcium-induced 1,25(OH)2D
synthesis, one can postulate that their mechanism of action
is not simply limited to inhibition of the PTH/PTHrP type 1
receptor. This observation confirms the results obtained
in vitro concerning the inhibition of bone resorption by
C-PTH fragments, which, besides PTH(1–84) and (1–34), also
Table 2 | Influence of rC-PTH fragment mixture on the biological responses to rPTH(1–34)
Groups Parameters PTX-solvent
PTX-rmixture
(0.18 nmol/kg/h)
PTX-rPTH(1–34)
(0.06 nmol/kg/h)
PTX-rPTH(1–34)+rmixture
(0.18 mmol/kg/h)
PTX-rPTH(1–84)
(0.09 nmol/kg/h)
N 9 10 12 8 8
Weight (g) 281728 264722 278726 254717 256720
Ca2+ (mmol/l) 1.0470.03 0.9970.07 1.3370.09b,d 1.3270.12b,d 1.3170.07b,d
Ca total (mmol/l) 1.9570.07 1.9570.17 2.5570.20b,d 2.5970.27b,d 2.4970.19b,d
Phosphorus (mmol/l) 3.0570.37 3.1670.32 2.6670.38 2.8770.28 2.4470.30a,d,f
Alk. phos. (U/l) 2567101 3327100 301788 278763 2827106
25(OH)D (nmol/l) 75722 71710 63710 6379 7676
1,25(OH)2D (pmol/l) 133742 67720
b 234796b,d 98726c,h 122733d,g
rPTH(1–4) (pmol/l) 0 0 0 0 3.773.5b,d,g,h
rPTH(13–34) (pmol/l) 0.570.4 30.7719.8b 0d 9.875.0d,f 7.677.3d,e
ANOVA, analysis of variance; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; PTX, parathyroidectomized.
Results are means7s.d. obtained at time 48 h. Differences between groups were analyzed by one-way ANOVA on log-transformed values, followed by the
Student–Newman–Keuls test.
PTX solvent vs other groups: aPo0.01; bPo0.001. PTX-rmixture vs other PTX-PTH-infused groups: cPo0.05; dPo0.001. PTX-rPTH(1–34) vs the two other rPTH-infused groups:
ePo0.005; fPo0.01; gPo0.001. PTH-rPTH(1–34)+rmixture vs rPTH(1–84): hPo0.001.
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Figure 2 | CYP27B1 and 1,25(OH)2D responses to various rat PTH
preparations. Response of the CYP27B1/GAPDH ratio and of
1,25(OH)2D to various rPTH preparations alone or in combination.
Results are means7s.d. obtained at time 48 h. Statistical analysis of
log-transformed values by one-way ANOVA (analysis of variance),
followed by the Student–Newman–Keuls test. (a) Different from
sham-solvent (þPo0.05); different from PTX-solvent (Po0.05).
(b) Different from PTX-rPTH(1–34) (þ þ þPo0.001); different from
PTX-rPTH mixture (Po0.05;   Po0.001).
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affect 1,25(OH)2D, prostaglandin E2, and interleukin-11.
6 It is
thus probably unlikely that the inhibitory effect could be
related to PTH/PTHrP type 1 receptor internalization, an
action of PTH(7–84) in some renal cells,19 but is probably
linked more to the activation of a not-yet-cloned C-PTH
receptor.2
For the first time, an inhibitory impact of C-PTH
fragments on 1,25(OH)2D synthesis has been demonstrated.
It is probably related to the fact that all prior studies in vivo
in PTX rats used hPTH preparations,3–5 which had no
stimulatory effect on 1,25(OH)2D synthesis in our experi-
ments and at the doses tested. Inhibition was seen at near
physiological concentrations of rPTH(1–84) and rC-PTH
fragments and in the absence of noticeable actions of rC-PTH
fragments on calcium or phosphate concentrations. This
indicates that the main function of rC-PTH fragments at
physiological levels may be to control 1,25(OH)2D synthesis.
It may be part of a mechanism to regulate the participation of
bone in circulating calcium concentration. When
1,25(OH)2D is elevated, the intestinal absorption of calcium
is enhanced, the transcription of the PTH gene is reduced,20
the production and secretion of C-PTH fragments by the
parathyroid glands12 are augmented and measurable in the
circulation.10,11 This should result in a decrease of bone
resorption.6 The reverse would be true when 1,25(OH)2D
level is low. Our findings are pertinent to 1,25(OH)2D
synthesis in renal failure, as it is reduced very early when only
25% of the glomerular filtration rate is impaired.21,22 The
accumulation of C-PTH fragments is also a very early event23
and may be involved in the early 1,25(OH)2D diminution.
MATERIALS AND METHODS
Experimental animals
Male Sprague–Dawley rats, weighing 125–150 g and purchased from
Charles-River Canada (St-Constant, QC, Canada), were maintained
according to the guidelines of the Canadian Council on Animal Care
on a normal chow diet supplemented with 1% calcium gluconate in
water for the duration of the protocol and for 1 week before any
manipulation.
Experimental protocol
The experimental protocol was approved by the Animal Care
Committee of our center. Eight groups of 8–12 rats were studied.
Parathyroidectomy was performed selectively in seven groups under
isoflurane anesthesia delivered in NO2/O2 (4:1), whereas the other
group was sham-operated under similar conditions. Parathyroi-
dectomy was considered effective when concentration of ionized
calcium (Ca2þ ) decreased below 1.10 mmol/l between 7 and 10 days
post-surgery. Then, under the same type of anesthesia, an osmotic
minipump (Alzet model 1003D, 1 ml/h for 3 days; Durect Corp.,
Cupertino, CA, USA) was implanted subcutaneously in the dorsal
area in all rats to deliver PTH preparation intravenously via a silastic
catheter (0.64 mm, inner diameter, Dow Corning Corp., Midland,
MI, USA) introduced in the right jugular vein. The PTH
preparations were dissolved in 2.2% L-cysteine HCl in 0.9% saline
in a final volume of 130 ml, at the required concentration. Two
groups, one sham and one PTX group, were infused with solvent
alone, two PTX groups with hPTH(1–84) at 0.24 nmol/kg/h and
hPTH(1–34) at 0.12 nmol/kg/h, two PTX groups with rPTH(1–84) at
0.09 nmol/kg/h and rPTH(1–34) at 0.06 nmol/kg/h, and two PTX
groups with rC-PTH fragment mixture (30% rPTH(7–84) and 70%
rPTH(39–84) alone at 0.18 nmol/kg/h or with rPTH(1–34) at
0.06 nmol/kg/h). Blood was obtained by the tail vein to measure
Ca2þ daily for 3 days before minipump implantation and at 4, 24,
and 48 h after. The animals were 9–10 weeks old when killed under
general anesthesia at 48 h by exsanguination through the abdominal
vena cava.
Experimental methods
Products. All hPTH and rPTH peptides were obtained from
BACHEM, some in their regular catalog but some newly synthesized
for this project.
Biochemistry. Ca2þ was quantified by Ca2þ -specific electrode
(Rapid Lab Model 348, Bayer Diagnostics, Toronto, ON, Canada).
Total calcium, phosphate, albumin, creatinine, and alkaline
phosphatase were measured by colorimetric methods adapted to
multianalyzer evaluation. 25(OH)D was quantified by a radio-
immunoassay from IDS Inc. (Fountain Hills, AZ, USA).
1,25(OH)2D was analyzed by enzyme-linked immunosorbent assay
from ALPCO Diagnostics (Windham, NH, USA). hPTH and rPTH
were assessed by PTH enzyme-linked immunosorbent assays
provided by Immutopics International (San Clemente, CA, USA).
Two hPTH assays were undertaken with specificity for regions 1–4
(bioactive hPTH) and 12–23 (intact hPTH) of the hPTH structure.24
The first detects hPTH(1–84) but not hPTH(7–84), whereas the
second detects both molecular forms equally. Similar rPTH assays
were performed, but their epitopes ((1–4) and (13–34)) have not
been more precisely defined. Again, the first assay detects
rPTH(1–84) but not rPTH(7–84), whereas the second detects both
molecular forms equally. These assays served to measure PTH in
serum at the time of killing.
RNA processing. Total renal RNA was extracted by the
guanidine isothiocyanate and lithium chloride procedure described
in Lemay et al.25 Before reverse transcription, mRNA was treated
with DNase (Qiagen, Mississauga, ON, Canada) and purified with a
RNeasy kit from Qiagen.
For reverse transcription, 1 mg of DNase-treated total RNA was
converted to cDNA with the First-Strand cDNA synthesis kit using
pd(N)6 as primer. cDNA was purified with ChargeSwichPCR Clean-
Up kit (Invitrogen, Burlington, ON, Canada) and resuspended in
30 ml of Tris buffer (10 mM, pH 8.5).
Quantitative PCR
The expression of specific mRNAs was quantified in a Rotor-
Gene3000 Real-Time DNA Amplification system (Corbett Research,
Sydney, NSW, Australia). Briefly, 2.25 ml (GAPDH) or 4.5ml
(CYP27B1) of the reverse transcription reaction was amplified with
specific primers and Platinum SYBR Green qPCR SuperMix UDG
(Invitrogen), in a volume of 25 ml according to the manufacturer’s
procedure under the following conditions: 951C for 3 min, followed
by 45 cycles of 951C for 10 s, 591C for 30 s, and 721C for 30 s. The
primers were designed to generate CYP27B1 and GAPDH cDNA
fragments, as described previously with sequences by St-Arnaud
et al.26 (CYP27B1) and Tso et al.27 (GAPDH). Standard curves were
charted, with an internal control for each gene, and the relative
abundance value obtained was divided by the value derived from
the housekeeping gene standard curve, giving a relative quantitative
ratio.
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Statistical analysis
The results are means7s.d. Differences between groups were
ascertained by analysis of variance, followed by the Student–New-
man–Keuls multiple comparison 2 2 test.
ACKNOWLEDGMENTS
This work was made possible by an educational grant from NPS
Pharmaceuticals (Toronto). There is no other disclosure to this work.
We thank Manon Livernois for typing this paper and Ovid Da Silva for
editing it.
REFERENCES
1. Brossard JH, Cloutier M, Roy L et al. Accumulation of non-(1–84) molecular
form of parathyroid hormone (PTH) detected by intact PTH in renal
failure: importance in the interpretation of PTH values. J Clin Endocrinol
Metab 2000; 81: 3923–3929.
2. Murray TM, Rao LG, Divieti P et al. Parathyroid hormone secretion and
action: evidence for discrete receptors for the carboxyl-terminal region
and related biological actions of carboxyl-terminal ligands. Endocr Rev
2005; 26: 78–113.
3. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal
resistance in uremia. Kidney Int 2000; 58: 753–761.
4. Nguyen-Yamamoto L, Rousseau L, Brossard JH et al. Synthetic carboxyl-
terminal fragments of PTH decrease ionized calcium concentration in rats
by acting on a receptor different from the PTH/PTHrP receptor.
Endocrinology 2001; 142: 1386–1392.
5. Langub MC, Monier-Faugere MC, Wang G et al. Administration of
PTH-(7–84) antagonizes the effects of PTH-(1–84) on bone in rats with
moderate renal failure. Endocrinology 2003; 144: 1135–1138.
6. Divieti P, John MR, Ju¨ppner H et al. Human PTH-(7–84) inhibits bone
resorption in vitro via actions independent of the type 1 PTH/PTHrP
receptor. Endocrinology 2002; 143: 171–176.
7. Divieti P, Inomata N, Chapin K et al. Receptors for the carboxyl-terminal
region of PTH(1–84) are highly expressed in osteocytic cells.
Endocrinology 2001; 142: 916–925.
8. Inomata N, Akiyama M, Kubota N et al. Characterization of a novel
PTH-receptor with specificity for the carboxyl-terminal region of
PTH(1–84). Endocrinology 1995; 136: 4732–4740.
9. Divieti P, Geller AI, Suliman G et al. Receptors specific for the
carboxyl-terminal region of parathyroid hormone on bone-derived
cells: determinants of ligand binding and bioactivity. Endocrinology 2005;
146: 1863–1870.
10. Cloutier M, Brossard JH, Gascon-Barre´ M et al. Lack of involution of
hyperplastic parathyroid glands in dogs. Adaptation via a decrease
in the calcium stimulation set point and a change in secretion profile.
J Bone Miner Res 1994; 9: 621–629.
11. Cloutier M, Gagnon Y, Brossard JH et al. Adaptation of parathyroid
function to IV 1,25-dihydroxyvitamin D3 or partial parathyroidectomy in
normal dogs. J Endocrinol 1997; 155: 133–141.
12. Hanley DA, Matus S, Cheng H. Effect of 1,25-dihydroxyvitamin D3 on
secretion of parathyroid hormone fragments in cultured bovine
parathyroid cells. Clin Invest Med 1996; 19: S23.
13. Trechsel U, Eisman JA, Fischer JA et al. Calcium-dependent, parathyroid
hormone-independent regulation of 1,25-dihydroxyvitamin D. Am J
Physiol 1980; 239: E119–E124.
14. Hulter HN, Halloran BP, Toto RD et al. Long-term control of plasma
calcitriol concentration in dogs and humans: dominant role of plasma
calcium concentration in experimental hyperparathyroidism. J Clin Invest
1985; 76: 695–702.
15. Bushinsky DA, Riera GS, Favus MJ et al. Evidence that blood
ionized calcium can regulate serum 1,25(OH)2D3 independently of
parathyroid hormone and phosphorus in the rat. J Clin Invest 1985;
76: 1599–1604.
16. Weisinger JR, Favus MJ, Langman CB, Bushinsky DA. Regulation of
1,25-dihydroxyvitamin D3 by calcium in the parathyroidectomized,
parathyroid hormone-replete rat. J Bone Miner Res 1989; 4: 929–935.
17. Clements MR, Johnson L, Fraser DR. A new mechanism for induced
vitamin D deficiency in calcium deprivation. Nature 1987; 125: 62–64.
18. Armbrecht HJ, Boltz MA, Hodam TL. PTH increases renal 25(OH)D3-1a-
hydroxylase (CYP1A) mRNA but not renal 1,25(OH)2D3 production in
adult rats. Am J Physiol 2003; 284: F1032–F1036.
19. Sneddon WB, Syme CA, Bisello A et al. Activation-independent
parathyroid hormone receptor internalization is regulated by NHERF1
(EBP50). J Biol Chem 2003; 278: 43787–43796.
20. Silver J, Naveh-Many T, Mayer H et al. Regulation by vitamin D
metabolites of parathyroid gene transcription in vivo in the rat. J Clin
Invest 1986; 78: 1296–1301.
21. St John A, Thomas MB, Cavies CP et al. Determinants of intact parathyroid
hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate
renal failure. Nephron 1992; 61: 422–427.
22. Pitts TO, Piraino BH, Mitro R et al. Hyperparathyroidism and
1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe
renal failure. J Clin Endocrinol Metab 1988; 67: 876–881.
23. Brossard JH, Lepage R, Cardinal H et al. Influence of glomerular filtration
rate on non-(1–84) parathyroid hormone (PTH) detected by intact PTH
assays. Clin Chem 2000; 46: 697–703.
24. D’Amour P, Brossard JH, Rousseau L et al. Structure of non-(1–84) PTH
fragments secreted by parathyroid glands in primary and secondary
hyperparathyroidism. Kidney Int 2005; 68: 998–1007.
25. Lemay J, Demers C, Hendy GN et al. Expression of the 1,25-
dihydroxyvitamin D3-24-hydroxylase gene in rat intestine: response to
calcium, vitamin D3 and calcitriol administration in vivo. J Bone Miner Res
1995; 10: 1148–1157.
26. St-Arnaud R, Messerlian S, Moir JM et al. The 25-hydroxyvitamin
D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency
rickets (PDDR) disease locus. J Bone Miner Res 1997; 12: 1552–1559.
27. Tso JY, Sun XH, Kao TH et al. Isolation and characterization of rat and
human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic
complexity and molecular evolution of the gene. Nucleic Acids Res 1985;
13: 2485–2502.
Kidney International (2007) 72, 1330–1335 1335
M Usatii et al.: C-PTH fragments and 1,25(OH)2D synthesis o r i g i n a l a r t i c l e
